FDA Cites Barr Seasonale TV Ad For Misleading Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
The direct-to-consumer ad fails to reveal that patients may experience breakthrough bleeding or spotting for up to a year, an FDA ad division letter states. The agency also says the risk information contained in the ad is obscured by the "compelling visuals."
You may also be interested in...
Barr Launches New Seasonale Ad, Increases Emphasis On Safety Risks
The third version of Barr’s television ad responds to issues previously objected to by FDA’s ad division.
Barr Launches New Seasonale Ad, Increases Emphasis On Safety Risks
The third version of Barr’s television ad responds to issues previously objected to by FDA’s ad division.
Barr To File Seasonale Lo NDA By June 30
As Barr prepares to extend the Seasonale franchise, the company will introduce a new DTC TV campaign for the original formulation in late June or early July after FDA signs off on the ads. The company anticipates launching Seasonique in the fall, pending FDA approval of the extended-regimen contraceptive.